Investing Profile

Christopher de Souza

InvestorVC
VP Business Development at Skyepharma- Fully integrated CDMO
broadviewventures.org/team/Boston, Massachusetts
Photo of Christopher de Souza, Vice President at Skyepharma- Fully integrated CDMO

Signal uses Gmail to reveal intro paths. Email content is never read.

Sign in with Google →
Hotmail Network
4899 CONNECTIONS
Hotmail Network
4899 CONNECTIONS
Hotmail Network
4899 CONNECTIONS
Novartis Network
53 CONNECTIONS
Novartis Network
53 CONNECTIONS
cb
$100K - $5.0M
$1.5M
10
CompanyStageDateRound SizeTotal Raised
Mellitus
Debt FinancingApr 2017$1M
$1M
Gila Therapeutics
Series AFeb 2016$3M
$3M
Epirium Bio
Debt FinancingMay 2015$1M
$86M
Co-investors: Paul Berns (ARCH Venture Partners)
Pulmokine
Debt FinancingMar 2015$1M
$1M
Acesion Pharma
Series UnknownDec 2014$3M
$51M
Co-investors: Tim Shannon (Canaan Partners)
DecImmune Therapeutics
Series UnknownFeb 2013$2M
$2M
Laurantis Pharma
Series UnknownSep 2012$7M
$7M
Herantis Pharma
Series AAug 2012$1M
$1M
Senior Scientist NovartisPresent
Director, Strategic Alliances NovartisPresent
Co-Chair, Business Development Committee HotmailPresent
VP Business Development Skyepharma- Fully integrated CDMOPresent
Business Development Consultant Diagnostics For AllPresent
Strategic Advisor and BOD member Metaome Science Informatics Pvt LtdPresent
Director Broadview Ventures IncPresent
Board Observer Herantis Pharma Plc.Present
Board Observer Allosteros Therapeutics Inc.Present
Board Observer HotmailPresent
Board Observer Acesion PharmaPresent
Board Director MassBioPresent
Board Director HotmailPresent
Chair, Translation Awards Committee British Heart FoundationPresent
Director Longview Healthcare VenturesPresent
Member, Board of Director Giner, Inc.Present
University of Mumbai BSc and MSc Zoology and Biochemistry
Louisiana State University MS and PhD Endocrine Physiology
Rutgers University - Newark MBA Management